Verzenios® ▼ (abemaciclib): Tumörstadier i MONARCH

Detailed Information

Abemaciclib is indicated for the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.¹

MONARCH Clinical Trials

These indications correspond with inclusion criteria in the MONARCH clinical trials. Patients in the MONARCH clinical trials were required to have

• locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease in MONARCH 3 and

• locally advanced disease not amenable to curative treatment by surgery or metastatic disease in MONARCH 2.²

In MONARCH 3, 11 (3.4%) out of 328 patients in the abemaciclib arm presented with locoregionally recurrent disease.³ 

In MONARCH 2, 16 (3.6%) out of 446 patients in the abemaciclib arm presented with recurrent locally advanced disease.²

References

1. Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646. https://doi.org/10.1200/jco.2017.75.6155

Glossary

HR+ = hormone receptor-positive

HER2- = human epidermal growth factor receptor 2-negative

MBC = metastatic breast cancer

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.